Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) have been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and two have given a strong buy recommendation to the company.
BAYRY has been the subject of several research analyst reports. DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Finally, Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th.
View Our Latest Stock Report on Bayer Aktiengesellschaft
Bayer Aktiengesellschaft Price Performance
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.06. Bayer Aktiengesellschaft had a positive return on equity of 16.77% and a negative net margin of 3.80%.The firm had revenue of $12.53 billion for the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.28 EPS for the current year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY.
The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics.
Featured Stories
- Five stocks we like better than Bayer Aktiengesellschaft
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.
